[1]王梅子,封康,陆遥,等.贝伐单抗治疗视网膜中央静脉阻塞（CRVO）继发黄斑水肿的短期疗效及影响因素分析[J].眼科新进展,2018,38(12):1176-1179.[doi:10.13389/j.cnki.rao.2018.0278]
　WANG Mei-Zi,FENG Kang,LU Yao,et al.Analysis of short-term outcomes and factors for intravitreal bevacizumab in the treatment of macular edema secondary to central retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(12):1176-1179.[doi:10.13389/j.cnki.rao.2018.0278]
点击复制

贝伐单抗治疗视网膜中央静脉阻塞（CRVO）继发黄斑水肿的短期疗效及影响因素分析/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年12期
页码:
1176-1179
栏目:
应用研究
出版日期:
2018-12-05

文章信息/Info

Title:
Analysis of short-term outcomes and factors for intravitreal bevacizumab in the treatment of macular edema secondary to central retinal vein occlusion
作者:
王梅子; 封康; 陆遥; 赵琳
100070　北京市，首都医科大学附属北京天坛医院眼科（王梅子）；100191　北京市，北京大学第三医院眼科中心，教育部重点实验室（封康，陆遥，赵琳）
Author(s):
WANG Mei-Zi; FENG Kang; LU Yao; ZHAO Lin
Department of Ophthalmology，Beijing Tiantan Hospital，Capital Medical University（WANG Mei-Zi），Beijing 100070，China；Department of Ophthalmology，Peking University Eye Center，Peking University Third Hospital，Key Laboratory of Vision Loss and Restoration，Ministry of Education（FENG Kang，LU Yao，ZHAO Lin），Beijing 100191，China
关键词:
视网膜中央静脉阻塞; 黄斑水肿; 贝伐单抗; 玻璃体内注射; 黄斑中心视网膜厚度
Keywords:
central retinal vein occlusion; macular edema; bevacizumab; intravitreal injection; central retinal thickness
分类号:
R774
DOI:
10.13389/j.cnki.rao.2018.0278
文献标志码:
A
摘要:
目的　观察玻璃体内注射贝伐单抗治疗视网膜中央静脉阻塞（central retinal vein occlusion，CRVO）继发黄斑水肿患者的临床特征及疗效，探讨对短期黄斑水肿恢复有影响的因素。方法　回顾性分析60例60眼CRVO继发黄斑水肿患者，采用玻璃体内注射贝伐单抗1.25 mg（0.05 mL），必要时重复治疗，随访3个月观察患者最佳矫正视力（best-corrected visual acuity，BCVA）及黄斑中心视网膜厚度（central retinal thickness，CRT）改变。根据治疗后3个月时CRT恢复水平，分析患者的年龄、病程、基线视力、基线CRT、高血压及糖尿病、黄斑囊样水肿（cystoid macular edema，CME）或视网膜下液体（subretinal fluid，SRF）情况对黄斑水肿恢复的影响。结果　BCVA从基线（0.897±0.395）LogMAR提高到治疗后1个月的（0.616±0.350）LogMAR，并稳定持续至治疗后3个月（P＜0.001），同时CRT从基线（721.2±180.8）μm降低到治疗后3个月的（392.1±185.4）μm（P＜0.001）。治疗后3个月56.7%的CME和超过90%的SRF均得到完全缓解。年龄和基线CRT低提示治疗后3个月时CRT恢复较好（P=0.036、0.037）。年龄大的患者（＞60岁）治疗后黄斑水肿消除更多（P=0.031），治疗后3个月时CRT更低（P=0.003）。结论　玻璃体内注射贝伐单抗能有效提高BCVA并降低CRT。年龄大和基线CRT低提示治疗后3个月时CRT恢复较好。CRT的降低主要取决于CME是否消除，而与SRF无关。
Abstract:
Objective　To investigate the clinical effects and the influence factors for short-term central retinal thickness （CRT） outcomes after intravitreal bevacizumab in patients with macular edema （ME） secondary to central retinal vein occlusion（CRVO）.Methods　Retrospective study was conducted in 60 eyes treated with intravitreal bevacizumab 1.25 mg （0.05 mL） for ME due to CRVO.Follow up was three months and additional injections were given for recurrent or persistent ME.Best corrected visual acuity （BCVA） and CRT were used to observe the changes after treatment.According to treatment response at 3 months based on CRT，baseline BCVA，CRT，age，CRVO duration，hypertension or diabetes mellitus，and the presence of cystoid macular edma（CME） or subretinal fluid（SRF） were analyzed for influence factors.Results　BCVA improved from （0.897±0.395）LogMAR at baseline to （0.616±0.350）LogMAR at 1 month and remained stable at 3 months，associated with a significant reduction in CRT from （721.2±180.8）μm to （392.1±185.4）μm （P＜0.001） after 3 months.About 56.7% of CME and more than 90% of SRF responded to treatment with a complete resolution at 3 months.Age （P=0.036） and low baseline CRT （P=0.037） were associated with a good 3 month prognosis.Patients＞60 years old achieved better CME resolution（P=0.031） and lower CRT （P=0.003） at 3 months.Conclusion　Intravitreal bevacizumab can significantly improve visual acuity and decreased CRT in patients with CRVO.Older age and lower baseline CRT maybe are the good predictors of short-term CRT outcomes.The retinal thickness response to bevacizumab depends on the resolution of CME，rather than SRF.

参考文献/References:

［1］　KLEIN R，KLEIN B E，MOSS S E，MEUER S M.The epidemiology of retinal vein occlusion：the Beaver Dam Eye Study［J］.Trans Am Ophthalmol Soc，2000，98：133-143.
［2］　ROGERS S，MCINTOSH R L，CHEUNG N，LIM L，WANG J J，MITCHELL P，et al.The prevalence of retinal vein occlusion：pooled data from population studies from the United States，Europe，Asia，and Australia［J］.Int Eye Disease Consortium，2010，117（2）：313-319.
［3］　BRAITHWAITE T，NANJI A A，LINDSLEY K，GREENBERG P B.Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion［J］.Cochranc Databasc Syst Rcv，2014，5：CD007325.
［4］　IVANOVSKA-ADJIEVSKA B，BOSKURT S，OROVCANEC N，DIMOVSKA-JORDANOVA V.The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions［J］.Clin Ophthalmol，2017，21（11）：1183-1190.
［5］　ACH T，HOEH A E，SCHAAL K B，SCHEUERLE A F，DITHMAR S.Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion［J］.Graefes Arch Clin Exp Ophthalmol，2010，248 （2）：155-159.
［6］　HOEH A E，RUPPENSTEIN M，ACH T，DITHMAR S.OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion［J］.Graefes Arch Clin Exp Ophthalmol，2010，248（11）：1567-1572.
［7］　BHISITKUL R B，CAMPOCHIARO P A，SHAPIRO H，RUBIO R G.Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography［J］.Ophthalmology，2013，120（5）：1057-1063.
［8］　KOURAKOS V，RAUSCHER A，SCHMIDBAUER J.Predictive value of OCT-controlled early response of macular edema secondary to retinal vein occlusion after intravitreal bevacizumab therapy［J］.Klin Monbl Augenheilkd，2018，［Epub ahead of print］.
［9］　The Central Vein Occlusion Study Group.Natural history and clinical management of central retinal vein occlusion［J］.Arch Ophthalmol，1997，115（4）：486-491.
［10］　GROVER S，MURTHY R K，BRAR V S，CHALAM K V.Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography［J］.Invest Ophthalmol Vis Sci，2010，51（5）：2644-2647.
［11］　GROVER S，MURTHY R K，BRAR V S，CHALAM K V.Normative data for macular thickness by high-definition spectral-domain optical coherence tomography （spectralis）［J］.Am J Ophthalmol， 2009，148（2）：266-271.
［12］　EPSTEIN D L，ALGVERE P V，VON WENDT G，SEREGARD S，KVANTA A.Bevacizumab for macular edema in central retinal vein occlusion：a prospective，randomized，double-masked clinical study［J］.Ophthalmology，2012，119（6）：1184-1189.
［13］　KORNHAUSER T，SCHWARTZ R，GOLDSTEIN M，NEUDORFER M，LOEWENSTEIN A，BARAK A.Bevacizumab treatment of macular edema in CRVO and BRVO：long-term follow-up.（BERVOLT study：Bevacizumab for RVO long-term follow-up）［J］.Graefes Arch Clin Exp Ophthalmol，2016，254（5）：835-844.
［14］　KHAN M，WAI K M，SILVA F Q，SRIVASTAVA S，EHLERS J P，RACHITSKAYA A，et al.Comparison of ranibizumab and bevacizumab for macular edema secondary to retinal vein occlusions in routine clinical practice［J］.Ophthalmic Surg Lasers Imaging Retina，2017，48（6）：465-472.
［15］　DECROOS F C，EHLERS J P，STINNETT S，FEKRAT S.Intravitreal bevacizumab for macular edema due to central retinal vein occlusion：perfused vs.ischemic and early vs.late treatment［J］.Curr Eye Res，2011，36（12）：1164-1170.
［16］　NOMA H，FUNATSU H，MIMURA T.Vascular endothelial growth factor and interleukin-6 are correlated with serous retinal detachment in central retinal vein occlusion［J］.Curr Eye Res，2012，37（1）：62-67.
［17］　SCOTT I U，VANVELDHUISEN P C，ODEN N L，IP M S，BLODI B A，HARTNETT M E，et al.Standard Care versus CfRVOSIG.Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion：standard care versus corticosteroid for retinal vein occlusion study report 10［J］.Ophthalmology，2011，118（2）：345-352.
［18］　SCOTT I U，VANVELDHUISEN P C，IP M S，BLODI B A，ODEN N L，KING J，et al.SCORE2 Investigator Group.Baseline factors associated with 6-month visual acuity and retinal thickness outcomes in patients with macular edema secondary to central retinal vein occlusion or hemiretinal vein occlusion：SCORE2 study report 4［J］.JAMA Ophthalmol，2017，135（6）：639-649.
［19］　JANUSCHOWSKI K，FELTGEN N，PIELEN A，SPITZER B，REHAK M，SPITAL G，et al.Bevacizumab Study Group Venous Occlusion，Meyer CH，Szurman GB.Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion［J］.Graefes Arch Clin Exp Ophthalmol，2017，255（3）：457-462.
［20］　KANG H M，CHUNG E J，KIM Y M，KOH H J.Spectral-domain optical coherence tomography （SD-OCT） patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion［J］.Graefes Arch Clin Exp Ophthalmol，2013，251（2）：501-508.
［21］　KOSS M，PFISTER M，ROTHWEILER F，REJDAK R，RIBEIRO R，CINATL J，et al.Correlation from undiluted vitreous cytokines of untreated central retinal vein occlusion with spectral domain optical coherence tomography［J］.Open Ophthalmol J，2013，7（1）：11-17.
［22］　GOKCE G，SOBACI G，DURUKAN A H，ERDURMAN F C.Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion［J］.Postgrad Med，2013，125（5）：51-58.
［23］　HWANG H S，CHAE J B，KIM J Y，KIM D Y.Association between hyperreflective dots on Spectral-Domain optical coherence tomography in macular edema and response to treatment［J］.Invest Ophthalmol Vis Sci，2017，58（13）：5958-5967.

相似文献/References:

[1]杨于力 刘勇 阴正勤 王一.眼部缺血综合征患者视网膜电图明视负向反应和震荡电位的变化特点[J].眼科新进展,2012,32(4):000.
[2]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[3]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[4]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[5]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[6]魏光杰 何佃菊.532nm绿激光全视网膜光凝术联合中药治疗视网膜中央静脉阻塞的疗效分析[J].眼科新进展,2013,33(10):000.
[7]刘李平 宋徽 肖云 曹小鹏 白润 陈珍.玻璃体注射雷珠单抗治疗缺血型视网膜中央静脉阻塞的临床观察[J].眼科新进展,2013,33(11):000.
[8]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[9]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[10]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[11]赵通,张利,尹玥,等.玻璃体内注射康柏西普联合后筋膜囊注射曲安奈德对视网膜中央静脉阻塞继发顽固性黄斑水肿患者的治疗效果[J].眼科新进展,2020,40(4):369.[doi:10.13389/j.cnki.rao.2020.0085]
　ZHAO Tong,ZHANG Li,YIN Yue,et al.Efficacy of intravitreal injection of Conbercept combined with posterior fascial capsular injection of Triamcinolone Acetonide for treatment of macular edema secondary to central retinal vein occlusion[J].Recent Advances in Ophthalmology,2020,40(12):369.[doi:10.13389/j.cnki.rao.2020.0085]
[12]董立红,张大传.不同时机视网膜激光光凝辅助康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的疗效分析[J].眼科新进展,2022,42(7):546.[doi:10.13389/j.cnki.rao.2022.0112]
　DONG Lihong,ZHANG Dachuan.Clinical effect of retinal photocoagulation and conbercept in the treatment of macular edema secondary to central retinal vein occlusion at different times[J].Recent Advances in Ophthalmology,2022,42(12):546.[doi:10.13389/j.cnki.rao.2022.0112]

更新日期/Last Update: 2018-12-04